Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia

Tsimberidou, AM; Stavroyianni, N; Viniou, N; Papaioannou, M; Tiniakou, M; Marinakis, T; Skandali, A; Sakellari, L; Yataganas, X

dc.contributor.author	Tsimberidou, AM	en
dc.contributor.author	Stavroyianni, N	en
dc.contributor.author	Viniou, N	en
dc.contributor.author	Papaioannou, M	en
dc.contributor.author	Tiniakou, M	en
dc.contributor.author	Marinakis, T	en
dc.contributor.author	Skandali, A	en
dc.contributor.author	Sakellari, L	en
dc.contributor.author	Yataganas, X	en
dc.date.accessioned	2014-03-01T01:53:06Z
dc.date.available	2014-03-01T01:53:06Z
dc.date.issued	2003	en
dc.identifier.issn	0008-543X	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26851
dc.subject	de novo acute myelogenous leukemia (AML)	en
dc.subject	postremission therapy	en
dc.subject	allogeneic stem cell transplantation	en
dc.subject	autologous stem cell transplantation	en
dc.subject	high-dose chemotherapy	en
dc.subject.classification	Oncology	en
dc.subject.other	ACUTE MYELOID-LEUKEMIA	en
dc.subject.other	BONE-MARROW TRANSPLANTATION	en
dc.subject.other	ACUTE NONLYMPHOCYTIC LEUKEMIA	en
dc.subject.other	INTENSIVE CONSOLIDATION CHEMOTHERAPY	en
dc.subject.other	ACUTE MYELOCYTIC-LEUKEMIA	en
dc.subject.other	FIRST COMPLETE REMISSION	en
dc.subject.other	CANCER STUDY-GROUP	en
dc.subject.other	MRC AML-10 TRIAL	en
dc.subject.other	PHASE-III TRIAL	en
dc.subject.other	MAINTENANCE CHEMOTHERAPY	en
dc.title	Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2003	en
heal.abstract	BACKGROUND. Postremission therapy is critical in maintaining complete remission (CR) in patients with de novo acute myelogenous leukemia (AML). The aim of this trial was to compare allogeneic stem cell transplantation (SCT), high-dose cytarabine (ara-C; HiDAC), and autologous SCT as postremission therapy in patients with de novo AML. METHODS. One hundred twenty patients age less than or equal to 60 years with previously untreated AML (non-M3) and a performance status score of less than or equal to 2 received induction therapy with 3 days of idambicin and 7 days of ara-C (IA). Patients in CR received one course of HiDAC. Subsequently, patients age ! 50 years with available HLA-compatible donors were assigned to receive allogeneic SCT; patients with "favorable" cytogenetics received a second course of HiDAC; and all others were randomized to a second course of HiDAC or autologous SCT. RESULTS. The IA combination induced CR in 99 patients (82.5%). With a median follow-up of 43 months (range, 18-64 years), the 3-year survival and failure-free survival (FFS) rates were 47% and 45%, respectively. The factors associated with longer survival were those identified for CR (i.e., age and cvtogenetics). Forty-nine patients (49%) received the assigned postremission therapy. Fifteen patients underwent allogeneic SCT. Nineteen patients underwent autologous SCT and 15 patients received a second course of HiDAC, after randomization. In the allogeneic SCT group, both the 3-year survival and the FFS rates were 73%. In the autologous SCT and HiDAC groups, the 3-year survival rates were 58% and 46%, respectively (P = 0.80), and the 3-year FFS rates were 42% and 33%, respectively (P = 0.83). CONCLUSIONS. The three postremission treatment groups had comparable survival. Allogeneic SCT is associated with a prolonged FFS.	en
heal.publisher	JOHN WILEY & SONS INC	en
heal.journalName	CANCER	en
dc.identifier.isi	ISI:000181816600016	en
dc.identifier.volume	97	en
dc.identifier.issue	7	en
dc.identifier.spage	1721	en
dc.identifier.epage	1731	en